Security key
92511W207
Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA)
CUSIP: 92511W207
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Total 13F shares
- 2,468,945
- Total 13F value
- $10,583,119
- Share change
- +2,274,817
- SEC-reported price per share
- $4.31
- Number of holders
- 31
- Value change
- +$10,479,755
- Number of buys
- 30
- Number of sells
- 4
- Shares outstanding
- 8,810,762
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
31
Top holders
10
VRCA full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Verrica Pharmaceuticals Inc. SEC filings
Verrica Pharmaceuticals Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 92511W207
Recent filing periods:
Ownership snapshot
Top reported holders of VRCA - Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Caligan Partners LP
Disclosed value leader
PERCEPTIVE ADVISORS LLC
Comparable rows
15/15
Latest evidence
30 Jun 2025
13D/G
13F
3/4/5
Lead comparable stake: 10%
13D/G row: Caligan Partners LP
Showing 1-6 of 15 holder rows.
Quick read
Caligan Partners LP leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Caligan Partners LP's linked filing trail.
Comparable ownership
Top 5
Caligan Partners LP
10%
ARMISTICE CAPITAL, LLC
10%
PERCEPTIVE ADVISORS LLC
1.6%
VANGUARD GROUP INC
2.3%
MARSHALL WACE, LLP
1.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Caligan Partners LP |
13D/G
13F
Company
|
10%
|
$7,769,760
15,856,653 shares
|
$0 | 31 Dec 2024 |
| ARMISTICE CAPITAL, LLC |
13D/G
13F
Company
|
10%
|
$7,480,813
9,235,571 shares
|
+$81,611 | 31 Mar 2025 |
| PERCEPTIVE ADVISORS LLC |
3/4/5
13D/G
10%+ Owner
|
1.6%
from 13D/G
|
$51,398,078
7,099,182 shares
|
— | 27 Dec 2023 |
| VANGUARD GROUP INC |
13F
Company
|
2.3%
|
$1,149,205
2,168,310 shares
|
— | 30 Jun 2025 |
| MARSHALL WACE, LLP |
13F
Company
|
1.4%
|
$65,696
123,953 shares
|
— | 30 Jun 2025 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
0.98%
|
$480,841
907,076 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
31
Shares
2,468,945
Rows available
31
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q1 2026 Across Filers
Q1 2026 holders
39
Q3 2025 holders
31
Holder diff
-8
| Investor | Q1 2026 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend